2812480-88-7
2812480-88-7
Chemical Structure
Biological Activity: MK-2060 is a monoclonal antibody factor XI inhibitor. MK-2060 binds to the A3 domain of coagulation factor XI (FXI), prevents FXIIa-mediated FXI activation, and blocks the binding/activation of FIX with FXIa, locking the zymogen in an inactive/non-activatable conformation, thereby prolonging aPTT. MK-2060 can be used in research on end-stage renal disease, ESRD requiring hemodialysis, and arteriovenous graft thrombosis[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MK-2060 | ≥99.0% | MK-2060 is a monoclonal antibody factor XI inhibitor. MK-2060 binds to the A3 domain of coagulation factor XI (FXI), prevents FXIIa-mediated FXI activation, and blocks the binding/activation of FIX with FXIa, locking the zymogen in an inactive/non-activatable conformation, thereby prolonging aPTT. MK-2060 can be used in research on end-stage renal disease, ESRD requiring hemodialysis, and arteriovenous graft thrombosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Presume J, et al. Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy. Cardiology and therapy. 2024 Mar;13(1):1-16.
- [2]. Jin M, et al. Potential Role of Contact Pathway Factors in Catheter-Related Thrombosis: Emerging Evidence and Therapeutic Strategies. Biomolecules. 2026 Aug 29;16(9):1256.
- [3]. Holzhauer S, et al. Factor XI Inhibition: Adult Evidence and Paediatric Considerations. Hamostaseologie. 2026 Aug 07.
- [4]. De Caterina R, et al. Factor XI inhibitors: cardiovascular perspectives. European heart journal. 2023 Jan 21;44(4):280-292. [Content Brief]
- [5]. Gailani D, et al. Measuring up: the need for new assays for factor (F) XI/FXIa inhibitor therapies[J]. Research and Practice in Thrombosis and Haemostasis, 2026.
- [6]. Del Toro-Mijares R, et al. Venous thromboembolism prevention and treatment with factor XI/XIa inhibitors: current status and future perspectives. Journal of thrombosis and thrombolysis. 2026 Jan;59(1):23-34.
